Enjoy complimentary customisation on priority with our Enterprise License!
The global allergy immunotherapies market size is estimated to grow by USD 1,010.37 million between 2022 and 2027 accelerating at a CAGR of 8.95%.
This report extensively covers market segmentation by product (SCIT and SLIT), type (allergic rhinitis, asthma, food allergy, and others), and geography (Europe, North America, Asia, and the Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges.
Allergies affect over 500 million people globally and are a rapidly growing health concern due to factors such as pollution and tobacco consumption. Although most allergies are non-remissive, some patients become resistant to them over time. The global allergy immunotherapies market is expected to grow significantly due to the high prevalence of allergies, particularly in developed countries like those in EMEA. The European population exceeds the global average, with 30% of the population having allergies, and this is expected to increase to 50% by 2025. With the increasing prevalence of allergies and awareness programs, the market has seen a rise in hospital admissions for severe allergic reactions in Europe. Research on novel therapies by various vendors is expected to lead to advances in immunology therapeutics for allergies.
View the Bestselling Market Research Sample
The global allergy immunotherapies market was negatively impacted by the COVID-19 outbreak in 2020 and 2021 as pharmaceutical companies shifted their focus toward developing COVID-19 drugs and vaccines. However, the resumption of allergy immunotherapy treatments without restrictions after the lifting of lockdowns in 2021 resulted in an increase in demand for allergy immunotherapies products, which is expected to drive market growth during the forecast period. The ongoing Russia-Ukraine war in 2022 has disrupted the supply chain of raw materials and sales of allergy immunotherapies products, resulting in a negative impact on the growth of the regional allergy immunotherapies market during the forecast period.
Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The prevalence of allergies and the high efficacy and safety of immunotherapies create a lucrative opportunity for pharmaceutical companies. This has led to the development of new immunotherapy products for allergies, resulting in increased FDA approvals over the last five years. Despite these approvals, the market still has a large unmet need, leading to extensive research and development for unaddressed indications such as peanut allergy. Aimmune Therapeutics Inc. and DBV Technologies SA have developed AR101 and Viaskin, respectively, which are expected to enter the market by 2020. This strong pipeline and expected approvals are likely to drive market growth during the forecast period.
The unclear pathogenesis and prognosis of various allergies pose a significant challenge to the global allergy immunotherapies market. Poor diagnosis due to the lack of effective diagnostic methods has resulted in companies conducting research on novel therapies to diagnose allergies. Recent advances have increased the number of patients being diagnosed early, making treatment more effective. Siemens Healthcare's IMMULITE 2000 XPi Immunoassay system is being used for the diagnosis of various medical conditions, including allergies. These advances are expected to identify new allergens, leading to better immunotherapies and driving market growth.
The unclear cause of various allergies is a significant challenge faced by the global allergy immunotherapies market. Misdiagnosis and ineffective treatment often lead to adverse events, reducing the drug adoption rate and posing a challenge to market growth. Despite recent approvals of highly effective SLITs, the risk of side effects remains high. The US FDA recommends auto-injectable epinephrine for patients receiving SLITs, but it may not be suitable for all patients, leading to low patient adherence. This is expected to significantly hinder market growth during the forecast period.
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Aimmune Therapeutics Inc. - The company offers allergy immunotherapies indicated for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens. The company operates in one reportable segment, which focuses on developing proprietary product candidates for the treatment of peanut and other food allergies.
The report also includes detailed analyses of the competitive landscape of the market and information about prominent and key market vendors, including:
Technavio’s report consists of a holistic analysis of the key development analysis, development stage, key market players, their marketing strategies, and powerful innovations to help any client gain a competitive edge.
The market share growth of the SCIT segment will be significant during the forecast period. Subcutaneous immunotherapy (SCIT), also known as allergy shots, is the most used type of immunotherapy for the treatment of various allergies. In SCIT, the patients receive small doses of allergen subcutaneously in the arm. Patients receive SCIT for long durations to increase their immunity to the allergy. SCITs have proven to be highly efficient for the treatment of various respiratory allergies, including allergic rhinitis (hay fever) and asthma. Despite being highly effective for the treatment of rhinitis and conjunctivitis, the market has witnessed an increasing preference for other treatment options, such as SLIT, resulting in the erosion of market share for the SCIT segment. Also, the recent clinical trial failures of prominent late-stage pipeline molecules, namely immunotherapies from Circassia, are expected to hamper the growth prospects of this segment. In addition, the recent advances in various SLITs are also expected to hamper the market growth of the segment during the forecast period.
Get a detailed analysis of various segments View Sample PDF
An increase in the prevalence of allergy rhinitis drives the growth of the global allergy immunotherapies market. Allergy rhinitis is an important risk factor that may lead to many diseases or disorders, including nasal polyps, sinusitis, and middle-ear infections, especially in children. The prevalence of allergic diseases is increasing worldwide, particularly in low- and middle-income countries, because of factors such as the lack of healthcare infrastructure and an adequate number of professionals, low access to healthcare facilities due to poor socioeconomic conditions, and inadequate treatment due to low awareness about the disease among physicians.
For more insights on the market share of various regions View PDF Sample now!
Europe is estimated to contribute 53% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The increasing prevalence of allergies in Germany, France, Italy, and the UK is a major factor driving the market growth in this region. Food allergies affect a significant share of the adult European population. In the affected population, the prevalence of oral allergy symptoms remains the highest, with a share of 80%-82%, followed by skin symptoms and rhino-conjunctivitis. The increasing need to treat these allergies is leading to the faster development of allergy immunotherapies in the region.
Allergy Immunotherapies Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2022 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.95% |
Market growth 2023-2027 |
USD 1,010.37 million |
Market structure |
Fragmented |
YoY growth (%) |
8.12 |
Regional analysis |
Europe, North America, Asia, and Rest of World (ROW) |
Performing market contribution |
Europe at 53% |
Key consumer countries |
US, Germany, France, UK, and Japan |
Competitive landscape |
Leading companies, Competitive Strategies, Consumer engagement scope |
Key companies profiled |
Adamis Pharmaceuticals Corp., Aimmune Therapeutics Inc., ALK Abello AS, ALLERGOPHARMA GmbH and Co. KG, Allergy Therapeutics PLC, Biomay AG, DBV Technologies SA, Desentum Oy, HAL Allergy BV, Immunomic Therapeutics Inc., Jubilant Pharmova Ltd., LETI Pharma SLU, LOFARMA Spa, Merck KGaA, Novartis AG, Optum Inc., Shionogi and Co. Ltd., Stallergenes Greer Ltd., Torii Pharmaceutical Co. Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.